Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $3.00 by Analysts at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) had its target price reduced by HC Wainwright from $5.00 to $3.00 in a research report released on Monday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($0.87) EPS, FY2024 earnings at ($4.19) EPS, Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.50) EPS and FY2025 earnings at ($2.41) EPS.

Other research analysts also recently issued research reports about the stock. Oppenheimer cut their target price on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. Royal Bank of Canada reduced their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.40.

Inovio Pharmaceuticals Stock Down 0.5 %

NASDAQ INO opened at $1.86 on Monday. Inovio Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $14.75. The business has a fifty day moving average of $3.19 and a 200-day moving average of $5.97. The stock has a market cap of $48.55 million, a price-to-earnings ratio of -0.89 and a beta of 0.84.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently made changes to their positions in INO. BNP Paribas Financial Markets lifted its stake in shares of Inovio Pharmaceuticals by 177.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 3,630 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter worth approximately $71,000. The Manufacturers Life Insurance Company purchased a new position in Inovio Pharmaceuticals in the second quarter valued at approximately $82,000. MetLife Investment Management LLC lifted its position in Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 8,546 shares in the last quarter. Finally, Atom Investors LP purchased a new stake in Inovio Pharmaceuticals during the third quarter worth approximately $103,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.